PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GenScript Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GenScript Announces Winners of iGEM CRISPR/Cas9 Grant - First-ever offering of commercial gene editing tools to synthetic biology competition teams - iGEM.org / GenScript.com
GenScript Announces Winners of iGEM CRISPR/Cas9 Grant

 

NewswireToday - /newswire/ - Piscataway, NJ, United States, 2016/08/04 - First-ever offering of commercial gene editing tools to synthetic biology competition teams - iGEM.org / GenScript.com. 1548:HK

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GenScript USA Inc., the number one global provider of gene synthesis services, today announced the winners of its CRISPR/Cas9 grants for this year’s Internationally Genetically Engineered Machine (iGEM) competition. This is the first year GenScript solicited iGEM proposals for applications that accelerate the CRISPR/Cas9 technology.

Teams from the Alverno High School, Blue Valley Center for Advanced Professional Studies, Boston University, College of William and Mary, Duke University, Eindhoven University of Technology, EPFL Switzerland, ETH Zurich University, Linköping University, Northwestern University, Texas Tech University, Tsinghua University, Tufts University, University of Warwick, UCC Ireland, and Worcester Polytechnic Institute will receive grants of up to US$5,000 for use as they choose to participate in the competition.

"The CRISPR/Cas9 grant allows a growing pool of young scientists to apply the genome editing technology to new systems and leverage our GenScript’s CRISPR/Cas9 offerings,” said Laura Geuss, Ph.D., GenScript’s CRISPR Services Product Manager. “GenScript congratulates the winners and wishes all iGEM teams lots of luck in their efforts to advance synthetic biology."

This is the seventh year GenScript has sponsored the worldwide synthetic biology competition. Teams previously sponsored by GenScript teams have won gold and silver medals.

All iGEM teams can receive a 20% off all gene synthesis and cloning costs ordered through GenScript.

Named 2015 Breakthrough of the Year by the journal Science, the genome-editing technology CRISPR has impacted nearly every area of genetic research. GenScript began developing and offering CRISPR genome editing products and services for researchers starting in June 2013. These include target-validated gRNA constructs, a custom construct service powered by a proprietary gDNA design tool, genome-scale gRNA libraries, and mammalian cell-line editing services. The company’s partnership with Dr. Feng Zhang’s laboratory at the Broad Institute of MIT and Harvard, and its leading expertise in gene synthesis and genome editing, allow for versatility in tackling CRISPR projects.

About GenScript

GenScript (genscript.com) is the world leader in gene synthesis, peptide, protein, and antibody research partner in the world. Since its founding in 2002, GenScript has grown exponentially through our collaboration with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. We provide life science services and products to scientists in over 100 countries worldwide. As of today, we are recognized as having built the best-in-class capacity and capability for biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, and in vitro and in vivo pharmacology all with the goal to Make Research Easy.

About iGEM
iGEM (iGEM.org) is a non-profit organization that is dedicated not only to the advancement of synthetic biology, but also to the education and collaboration of all people involved. This is done through the fostering of an open community and friendly competition.

Organized by the Massachusetts Institute of Technology (MIT), the International Genetically Engineered Machine (iGEM) competition has long been hailed as the largest Synthetic Biology competition aimed at high school, undergraduate, and graduate students. With 300 teams this year from top universities worldwide, the scale of this competition continues to grow each year. This event gives young students the opportunity to explore Synthetic Biology and its many uses in tackling everyday issues facing the world.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GenScript Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GenScript Announces Winners of iGEM CRISPR/Cas9 Grant

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GenScript USA, Inc. | iGEM CRISPR/Cas9 Grant
Publisher Contact: Press Office - GenScript.com 
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenScript Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GenScript Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)